BioRestorative Therapies annual revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioRestorative Therapies Revenue Growth & History (BRTX)
BioRestorative Therapies reported $359,700 in revenue for fiscal 2025, a decrease of 10.30% from the previous fiscal year.
View full BioRestorative Therapies company overviewBioRestorative Therapies annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $359,700 | −$41,300 | −10.30% |
| 2024 | 2024-12-31 | $401,000 | $255,200 | +175.03% |
| 2023 | 2023-12-31 | $145,800 | $26,000 | +21.70% |
| 2022 | 2022-12-31 | $119,800 | $73,800 | +160.43% |
| 2021 | 2021-12-31 | $46,000 | −$31,000 | −40.26% |
| 2020 | 2020-12-31 | $77,000 | −$53,000 | −40.77% |
| 2019 | 2019-12-31 | $130,000 | $19,000 | +17.12% |
| 2018 | 2018-12-31 | $111,000 | $30,000 | +37.04% |
| 2017 | 2017-12-31 | $81,000 | $44,645 | +122.80% |
| 2016 | 2016-12-31 | $36,355 | −$592,560 | −94.22% |
| 2015 | 2015-12-31 | $628,915 | $212,919 | +51.18% |
| 2014 | 2014-12-31 | $415,996 | $414,316 | +24661.67% |
| 2013 | 2013-12-31 | $1,680 | −$13,909 | −89.22% |
| 2012 | 2012-12-31 | $15,589 | $15,589 | — |
| 2011 | 2011-12-31 | $0 | — | — |
BioRestorative Therapies quarterly revenue
Q3.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $23,170 | −$1,830 | −7.32% |
| Q4 2025 | 2025-12-31 | $19,600 | −$23,700 | −54.73% |
| Q3 2025 | 2025-09-30 | $11,800 | −$221,800 | −94.95% |
| Q2 2025 | 2025-06-30 | $303,300 | $214,200 | +240.40% |
| Q1 2025 | 2025-03-31 | $25,000 | −$10,000 | −28.57% |
| Q4 2024 | 2024-12-31 | $43,300 | $24,000 | +124.35% |
| Q3 2024 | 2024-09-30 | $233,600 | $202,900 | +660.91% |
| Q2 2024 | 2024-06-30 | $89,100 | $24,600 | +38.14% |
| Q1 2024 | 2024-03-31 | $35,000 | $3,700 | +11.82% |
| Q4 2023 | 2023-12-31 | $19,300 | $15,600 | +421.62% |
| Q3 2023 | 2023-09-30 | $30,700 | $1,700 | +5.86% |
| Q2 2023 | 2023-06-30 | $64,500 | −$6,600 | −9.28% |
| Q1 2023 | 2023-03-31 | $31,300 | $15,300 | +95.63% |
| Q4 2022 | 2022-12-31 | $3,700 | −$1,300 | −26.00% |
| Q3 2022 | 2022-09-30 | $29,000 | $21,000 | +262.50% |
| Q2 2022 | 2022-06-30 | $71,100 | $56,100 | +374.00% |
| Q1 2022 | 2022-03-31 | $16,000 | −$2,000 | −11.11% |
| Q4 2021 | 2021-12-31 | $5,000 | −$12,000 | −70.59% |
| Q3 2021 | 2021-09-30 | $8,000 | −$7,000 | −46.67% |
| Q2 2021 | 2021-06-30 | $15,000 | −$4,000 | −21.05% |
| Q1 2021 | 2021-03-31 | $18,000 | −$8,000 | −30.77% |
| Q4 2020 | 2020-12-31 | $17,000 | −$15,000 | −46.88% |
| Q3 2020 | 2020-09-30 | $15,000 | −$23,000 | −60.53% |
| Q2 2020 | 2020-06-30 | $19,000 | −$12,000 | −38.71% |
| Q1 2020 | 2020-03-31 | $26,000 | −$3,000 | −10.34% |
| Q4 2019 | 2019-12-31 | $32,000 | $3,000 | +10.34% |
| Q3 2019 | 2019-09-30 | $38,000 | $12,000 | +46.15% |
| Q2 2019 | 2019-06-30 | $31,000 | −$6,000 | −16.22% |
| Q1 2019 | 2019-03-31 | $29,000 | $10,000 | +52.63% |
| Q4 2018 | 2018-12-31 | $29,000 | −$9,000 | −23.68% |
| Q3 2018 | 2018-09-30 | $26,000 | $10,000 | +62.50% |
| Q2 2018 | 2018-06-30 | $37,000 | $17,000 | +85.00% |
| Q1 2018 | 2018-03-31 | $19,000 | $12,000 | +171.43% |
| Q4 2017 | 2017-12-31 | $38,000 | $31,925 | +525.51% |
| Q3 2017 | 2017-09-30 | $16,000 | $11,000 | +220.00% |
| Q2 2017 | 2017-06-30 | $20,000 | $3,845 | +23.80% |
| Q1 2017 | 2017-03-31 | $7,000 | −$2,125 | −23.29% |
| Q4 2016 | 2016-12-31 | $6,075 | −$193,052 | −96.95% |
| Q3 2016 | 2016-09-30 | $5,000 | −$91,122 | −94.80% |
| Q2 2016 | 2016-06-30 | $16,155 | −$132,609 | −89.14% |
| Q1 2016 | 2016-03-31 | $9,125 | −$175,777 | −95.06% |
| Q4 2015 | 2015-12-31 | $199,127 | $119,377 | +149.69% |
| Q3 2015 | 2015-09-30 | $96,122 | −$63,808 | −39.90% |
| Q2 2015 | 2015-06-30 | $148,764 | −$27,177 | −15.45% |
| Q1 2015 | 2015-03-31 | $184,902 | $184,527 | +49207.20% |
| Q4 2014 | 2014-12-31 | $79,750 | $79,750 | — |
| Q3 2014 | 2014-09-30 | $159,930 | $159,805 | +127844.00% |
| Q2 2014 | 2014-06-30 | $175,941 | $175,516 | +41297.88% |
| Q1 2014 | 2014-03-31 | $375 | −$755 | −66.81% |
| Q4 2013 | 2013-12-31 | $0 | −$364 | −100.00% |
| Q3 2013 | 2013-09-30 | $125 | −$5,100 | −97.61% |
| Q2 2013 | 2013-06-30 | $425 | −$9,575 | −95.75% |
| Q1 2013 | 2013-03-31 | $1,130 | $1,130 | — |
| Q4 2012 | 2012-12-31 | $364 | — | — |
| Q3 2012 | 2012-09-30 | $5,225 | $5,225 | — |
| Q2 2012 | 2012-06-30 | $10,000 | — | — |
| Q1 2012 | 2012-03-31 | $0 | — | — |
| Q3 2011 | 2011-09-30 | $0 | — | — |
BioRestorative Therapies revenue growth trends
Over the last five reported fiscal years, revenue grew from $77,000 to $359,700, a compound annual growth rate of 36.11%. BioRestorative Therapies's latest reported quarter, Q1 2026, generated $23,170 in revenue, a decrease of 7.32% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review BioRestorative Therapies source filings ↗